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Sir,
The recent report by Kim et al.1 represents an interesting
attempt to assess the impact of a computer-assisted management
program on third-generation cephalosporin use and the incidence
of extended-spectrum b-lactamase (ESBL)-producing Klebsiella
pneumoniae in a Korean teaching hospital. The authors conclude
that their intervention study led to a decrease in third-generation
cephalosporin use from 103.2 to 84.9 DDD/1000 patient-days
and ultimately helped to control the spread of ESBL-producing
K. pneumoniae.
We would like to comment on some methodological problems
with the interpretation of the data. An effect on third-generation
cephalosporin use was seen when the average antibiotic use was
compared in the pre-intervention and the intervention phase. This
approach is, however, strongly discouraged by the authors of the
ORION statement for transparent reporting of intervention studies
in the field of antibiotic resistance, published in this journal last
year, as it does not take into account trends and temporary
changes.2 In fact, just by carefully examining the data provided
by the authors in Figure 2 of the article, it is evident that, despite
an initial decrease, there was a subsequent increase in the third-
generation cephalosporin use during the intervention period to
levels higher than before the intervention. It is also immediately
apparent that the incidence of ESBL-producing bacteria was
highest during the intervention period and only declined in the
maintenance period, where third-generation cephalosporin use
was even higher than in the pre-intervention period—a finding
that is hardly compatible with a successful intervention.
It is true that an interrupted time-series analysis—one of the
statistical methods suggested by the ORION statement for inter-
vention studies in the absence of a concurrent control group—
would not have been possible due to the lack of a sufficient
number of time points. A segmented regression analysis might,
however, have been a way to interpret the data more properly.3
Other biases may have distorted the study results. For
instance, outbreaks tend to cluster in certain wards. Thus, third-
generation cephalosporin use aggregated for the entire hospital
might not reflect the selection pressure in specific wards where
small-scale outbreaks may have occurred, leading to ecological
bias.4,5 Moreover, as antibiotic cross-resistance is frequent for
ESBL producers, changes in the use of a single class of anti-
biotics might be insufficient to decrease the overall selection
pressure. Finally, more detailed information about the infection
control policy (contact isolation, screening, local or national
hand hygiene promotion campaigns) for preventing the trans-
mission of ESBL-producing organisms would have been helpful.
In view of the worldwide increasing prevalence of multi-
resistant organisms and the link between antibiotic use and
resistance, we are in dire need of effective interventions to pro-
mote judicious antibiotic use.6 With the increasing availability
of computerized prescription systems in hospitals, computer-
assisted decision-making seems a promising tool to control anti-
biotic use. Studies like the one by Kim et al. confirm, however,
that despite the use of modern technologies, changing old habits
remains a difficult task.
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